-
- Academic Editors
-
-
-
Background: Tranexamic acid (TXA), an antifibrinolytic agent, has been
demonstrated to reduce blood loss and transfusion requirements in both cardiac
and non-cardiac surgery. However, the evidence regarding the efficacy of
intravenous TXA in aortic surgery has been seldomly analyzed. Therefore, the
current study was performed to address this question. Methods: Searches
of PubMed, EMBASE, OVID, Cochrane Library and CNKI were conducted comprehensively
for randomized controlled trials (RCTs) comparing intravenous TXA versus no-TXA.
Independently and in duplicate, we reviewed titles, abstracts and full-text
articles, extracted data and evaluated bias risks. A random effect or fixed
effect model was utilized to pool data. Results: The database search
yielded 4 RCTs involving 273 patients. Meta-analysis revealed that, there was a
significant reduction in bleeding volume within the first 4 hours
post-operatively [(weighted mean difference (WMD) = –74.33; 95% confidence interval (CI): –133.55 to –15.11; p =
0.01)], and the first 24 hours post-operatively [(WMD = –228.91; 95% CI:
–352.60 to –105.23; p = 0.0003)], post-operative red blood cell (RBC)
transfusion volume [(WMD = –420.00; 95% CI: –523.86 to –316.14; p